Corvus Pharmaceuticals, Inc. (CRVS)
NASDAQ: CRVS · IEX Real-Time Price · USD
1.780
-0.010 (-0.56%)
At close: Mar 28, 2024, 4:00 PM
1.781
+0.001 (0.06%)
After-hours: Mar 28, 2024, 4:15 PM EDT

Corvus Pharmaceuticals Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017201620152014
Net Income
-27.03-41.31-43.24-6-46.67-46.94-55.66-36.38-31.34-0.16
Depreciation & Amortization
0.150.370.460.630.740.850.840.590.150
Share-Based Compensation
2.152.694.235.757.357.146.233.830.430
Other Operating Activities
0.811.231.83-35.161.26-2.032.384.119.430.07
Operating Cash Flow
-23.94-27.02-36.72-34.78-37.32-40.99-46.21-27.86-11.33-0.1
Capital Expenditures
-0.03-0.25-0.01-0.08-0.03-0.36-0.27-2.2-1.750
Change in Investments
15.58-23.0321.5744.853.28-29.8485.09-40.36-90.290
Investing Cash Flow
15.54-23.2821.5644.773.26-30.1984.83-42.56-92.030
Share Issuance / Repurchase
7.86062.161.310.0265.271.4471.360.110
Other Financing Activities
--------94.8412.61
Financing Cash Flow
7.86062.161.310.0265.271.4471.3694.9512.61
Net Cash Flow
-0.54-50.34711.3-34.04-5.9140.060.95-8.4112.52
Free Cash Flow
-23.97-27.27-36.72-34.85-37.35-41.34-46.48-30.06-13.08-0.1
Free Cash Flow Per Share
-0.50-0.59-0.88-1.18-1.27-1.50-2.27-1.95-34.99-0.56
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).